Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus SYNERCID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus SYNERCID.
FORBAXIN vs SYNERCID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Synercid is a combination of two streptogramin antibiotics, quinupristin and dalfopristin, which bind to the 50S bacterial ribosome and inhibit protein synthesis. Quinupristin binds to the 23S rRNA near the peptidyl transferase center, while dalfopristin binds to a nearby site and enhances quinupristin's binding. The synergistic effect results in irreversible inhibition of bacterial protein synthesis.
IV: 500 mg every 12 hours, infused over 30 minutes.
7.5 mg/kg IV every 8 hours, administered as a 60-minute infusion.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
The terminal elimination half-life is approximately 0.85 hours for dalfopristin and 1.3 hours for quinupristin; however, the active metabolite of quinupristin has a half-life of about 3.5 hours, supporting twice-daily dosing.
Renal (60-70% unchanged), biliary/fecal (20-30%)
Primarily hepatic metabolism with biliary excretion; approximately 15% of the dalfopristin dose and 32% of the quinupristin dose are excreted unchanged in feces; renal excretion is minor (<5% for both components).
Category C
Category C
Antibiotic
Antibiotic